
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics is well positioned fundamentally because its BEST1 program has shown positive low-dose data, FDA-aligned microperimetry endpoints, and an over-enrolled 11-patient high-dose Cohort 2 that could validate a larger registrational path, with topline data on track for 1Q27. Its LCA5 Phase III is fully enrolled with dosing expected in 4Q26, while RDH12 IND clearance adds a third near-term clinical catalyst, reinforcing a diversified and increasingly de-risked rare eye disease pipeline. Financially, the company gains incremental support from a $10 million phentolamine milestone, royalties starting in the low teens, cash runway into 2029, and meaningful optionality from potential PRV monetization, with management and analysts highlighting low OpEx and attractive gross-margin economics.
Bears say
Opus Genetics is viewed negatively because its value depends heavily on two lead gene therapy programs that are still exposed to early clinical uncertainty, with OPGx-BEST1 supported only by a small, open-label five-patient Cohort 1 and OPGx-LCA5 not yet dosing after completion of the six-month run-in period. Regulatory risk is material since FDA alignment does not guarantee approval, while small patient populations, subretinal surgery, manufacturing setbacks, and intellectual property challenges could delay or limit commercialization and adoption. Financially, the company remains an unprofitable small-cap with significant cumulative losses, will likely need substantial additional capital despite a runway into 2029, and weaker PRV outcomes or higher development costs could force dilution.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Opus Genetics (IRD) Forecast
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares